When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Melanoma

Evidencia revisada por última vez: 15 Oct 2026
Tema actualizado por última vez: 08 May 2026

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • lesão pigmentada alterada (sinais do ABCDE)
  • lesão melanocítica que não se assemelha a nevos melanocíticos circundantes ("patinho feio")
  • sangramento espontâneo ou ulceração de uma lesão pigmentada
  • sintomas constitucionais
  • sinal ungueal: melanoníquia estriada persistente em uma única unha
  • sinal ungueal: sinal de Hutchinson
  • achados dermatoscópicos atípicos
  • linfadenopatia fixa
  • metástases em trânsito
Todos los datos

Factores de riesgo

  • exposição ao sol
  • história familiar de melanoma
  • história pessoal de melanoma
  • história pessoal de câncer de pele (inclusive danos actínicos)
  • história de nevos atípicos
  • Tipo de pele I ou II (pele branca) de Fitzpatrick
  • cabelo ruivo ou louro
  • alta densidade de sardas
  • uso de câmaras de bronzeamento
  • olhos claros
  • números elevados de nevos melanocíticos com aparência benigna
  • nevos congênitos grandes
  • imunossupressão
  • xeroderma pigmentoso
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • dermatoscopia
  • biópsia de pele
  • imuno-histoquímica
Todos los datos

Pruebas diagnósticas que deben considerarse

  • ultrassonografia
  • biópsia do linfonodo sentinela
  • tomografia computadorizada (TC) do tórax/abdome/pelve
  • PET do corpo inteiro
  • imagens do cérebro (tomografia computadorizada [TC] ou ressonância nuclear magnética [RNM])
  • análise mutacional em BRAF
  • Análise mutacional de NRAS
  • lactato desidrogenase (LDH) sérica
Todos los datos

Pruebas emergentes

  • Análise mutacional de CDKN2A

Algoritmo de tratamiento

Agudo

melanoma em estádio inicial (melanoma in situ, estádio I, estádio II)

melanoma em estádio III com linfonodos sentinelas negativos

melanoma em estádio III com linfonodos sentinelas positivos

melanoma em estágio III com linfonodos clinicamente positivos: ressecável

melanoma em estádio III com metástases satélite/em trânsito: doença limitada ressecável

melanoma em estádio III com metástases satélite/em trânsito: doença limítrofe ressecável ou irressecável

melanoma metastático em estádio IV

Colaboradores

Autores

Alvin J. X. Lee, PhD, FRCP

Consultant Medical Oncologist

Department of Medical Oncology

Guy's and St Thomas' NHS Foundation Trust

London

UK

Divulgaciones

AJXL declares that he has no competing interests.

Yin Wu, MRCP(UK), PhD

Wellcome Trust Career Development Fellow and Honorary Consultant Medical Oncologist

Centre for Inflammation Biology and Cancer Immunology

King's College London

Department of Medical Oncology

Guy's and St Thomas' NHS Foundation Trust

London

UK

Divulgaciones

YW is funded by the Wellcome Trust. YW consults for E15 VC and Boxer Capital, and has held advisory roles for Bristol Meyers Squibb and Sun Pharma.

Amanda Fitzpatrick, MRCP(UK), PhD

Medical Oncologist and Honorary Senior Lecturer

Guy's Cancer Centre

King's College

London

UK

Disclosures

AF has received research funding from Gilead Sciences and Daiichi Sankyo.

Pablo Fernandez-Peñas, MD, PhD, FACD

Professor of Dermatology

The University of Sydney

Sydney

Australia

Disclosures

PFP declares that he has no competing interests with the topic Melanoma. PFP has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, L’Oreal, LEO Pharma, Merck, Merck Sharp & Dohme, Novartis, Pfizer, and UCB; has given educational lectures for AbbVie, Amgen, Eli Lilly, Galderma, Johnson & Johnson, L’Oreal, LEO Pharma, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, UCB Pharma and Zuellig Pharma; has received research funding from Pfizer; has conducted clinical trials for AbbVie, Akesobio, Alumis, Amgen, Apogee, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CellDex, CSL, Chugai, Eisai, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Jiangsu Hengrui, KoBioLabs, Merck, Merck Sharp & Dohme, miRagen, Moderna, Nektar, Novartis, OncoSec, Pfizer, Regeneron, Sanofi, UCB Pharma.

Acknowledgements

Dr Alvin J. X. Lee, Dr Yin Wu, Dr Amanda Fitzpatrick, and Dr Pablo Fernandez-Peñas would like to gratefully acknowledge Dr Prachi Bhave, Dr Robyn P.M. Saw, Dr Sophie E. Papa, Dr Alexander M. Menzies, Dr Philip Friedlander, Dr Hobart W. Walling, and Dr Brian L. Swick, previous contributors to this topic.

Disclosures

PB has received honoraria from Bristol-Myers Squibb, MSD and Novartis and sponsorship from MSD and Novartis. RPMS is on the advisory board for Novartis, MSD, and Qbiotics and has previously been on the advisory board for Amgen; he has received honoraria from BMS and Novartis. SEP has received honoraria from BMS, MSD, and Novartis to attend conferences; she has participated in advisory boards for BMS, MSD, Amgen, Roche, and GSK. AMM has received honoraria from Novartis and BMS; he is on the advisory boards of MSD and Chugai. PF is a consultant for Genentech. HWW and BLS declare that they have no competing interests.

Peer reviewers

David Cassarino, MD, PhD

Assistant Professor

Department of Pathology and Laboratory Medicine

University of California

Los Angeles

CA

Disclosures

DC declares that he has no competing interests.

James DeBloom, MD

Dermatologist/Dermatologic Surgeon

President of the South Carolina Skin Cancer Center

Greenville

SC

Disclosures

JB declares that he has no competing interests.

Mai Brooks, MD, FACS

Associate Director

JCCC Women's Cancers Program Area

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles

CA

Disclosures

MB declares that she has no competing interests.

Karol Sikora, MA, MBBCh, PhD, FRCR, FRCP, FFPM

Medical Director

CancerPartnersUK

London

UK

Disclosures

KS declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma - cutaneous [internet publication].Full text

National Institute for Health and Care Excellence. Melanoma: assessment and management. Jul 2022 [internet publication].Full text

Seth R, Agarwala SS, Messersmith H, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023 Oct 20;41(30):4794-820.Full text  Abstract

Amaral T, Ottaviano M, Arance A, et al. Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jan;36(1):10-30.Full text  Abstract

Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022 Feb 10;40(5):492-516.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Melanoma images
  • Differentials

    • Nevos melanocíticos benignos/displásicos
    • Ceratose seborreica
    • Carcinoma basocelular pigmentado
    More Differentials
  • Guidelines

    • Suspected cancer: recognition and referral
    • Melanoma: assessment and management
    More Guidelines
  • Patient information

    Como tomar sol de forma segura

    Câncer de pele (melanoma): o que é?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer